[Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)]

Ned Tijdschr Geneeskd. 2012;156(36):A5104.
[Article in Dutch]


The decision whether to treat individuals not previously known to have cardiovascular disease is based on a new risk table in which Dutch research data on morbidity have been incorporated. An explanation of the roles of additional risk factors ignored in the cardiovascular risk function, such as a sedentary lifestyle and a high BMI, is provided. A method for estimating the cardiovascular risk in patients with diabetes mellitus and rheumatoid arthritis has been developed. New recommendations concerning the measurement of blood pressure at home and in the ambulatory setting have been formulated. The recommendations for the choice of antihypertensive drugs have been revised. The recommendations on handling therapy-resistant hypertension are provided. Recommendations for choosing statins based on a current cost-effectiveness analysis are provided.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antihypertensive Agents / therapeutic use*
  • Cardiovascular Agents / therapeutic use*
  • Cardiovascular Diseases / prevention & control*
  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy
  • Hypolipidemic Agents / economics
  • Hypolipidemic Agents / therapeutic use
  • Netherlands
  • Practice Guidelines as Topic*
  • Risk Assessment
  • Risk Management*


  • Antihypertensive Agents
  • Cardiovascular Agents
  • Hypolipidemic Agents